Kisunla Patient Assistance Program

(donanemab-azbt)

Key Takeaways

  1. Kisunla® (donanemab-azbt) is a prescription biologic medication used to treat adults with early symptomatic Alzheimer's disease, including mild cognitive impairment (MCI) due to Alzheimer's disease and mild Alzheimer's dementia.
  2. Before starting treatment, patients must have confirmed evidence of amyloid beta pathology in the brain.
  3. Kisunla works by targeting and helping remove amyloid beta plaques, which may slow the progression of Alzheimer's disease during its early stages.

 

Introduction

An Alzheimer’s disease diagnosis can be overwhelming for both patients and their loved ones. As memory, thinking, and daily functioning gradually decline, many families seek treatment options that may help slow the progression of the disease while preserving independence for as long as possible.

Kisunla is a prescription biologic medication approved for adults with early symptomatic Alzheimer’s disease, including mild cognitive impairment (MCI) due to Alzheimer’s disease and mild Alzheimer’s dementia. While it is not a cure and cannot restore lost memory or cognitive function, it may help slow clinical decline in eligible patients.

Accessing available prescription assistance programs through Prescription Hope may help eligible patients obtain Kisunla at a more affordable cost.

What Is the Kisunla Patient Assistance Program?

Understanding Kisunla Prescription Assistance

Some patients may have come across the Kisunla patient assistance program while researching how to find help paying for Kisunla.

But what is a patient assistance program?

Pharmaceutical manufacturers are aware that their brand-name medications are difficult for some Americans to pay for. Factors like gaps in government help and inadequate insurance leave many American patients prone to high out-of-pocket fees for the medications they need.

Thus, pharmaceutical manufacturers have created a solution: patient assistance programs.

These programs allow qualified patients access to the brand-name medications they need at a lower cost than normal. In order to be qualified for the program, patients must meet certain criteria such as income, insurance status, residency, and more.

The only drawback to these programs is that the application process is known to be tedious and complex. But Prescription Hope can help.

How Expert Advocates Help Make Kisunla More Affordable

Personalized Medication Assistance

Prescription Hope offers patient support services and Kisunula enrollment assistance to qualified patients through the application process and even after acceptance into the program. Our team of patient advocates is ready to come beside you and offer Kisunla application help, including form completion, coordinating with healthcare providers and pharmaceutical manufacturers, and more.

Ongoing Patient Support

Prescription Hope makes sure that qualified patients receive support and advocacy even after acceptance into a patient assistance program. Our team of patient advocates continues to offer long-term medication assistance throughout their treatment continuity. We help manage the administrative tasks that come with continued acceptance, such as prescription refill support, document updates, yearly renewals, program monitoring, and more.

Kisunla Price Comparison

vs

Prescription Hope logo

Estimated Retail Price*

$715.70

30-Day Supply

Prescription Hope Price

$70

Per Month, NO Matter The Retail Price

*Source: Drugs.com

Navigating Alzheimer’s Treatment Costs

While undergoing treatment for Alzheimer’s can be incredibly harrowing, your Alzheimer’s medication affordability doesn’t have to be. Our Kisunla cost assistance is only one prescription affordability program that Prescription Hope can help qualified patients with.

Our specialty medication support services are included in a monthly rate of $70.00 per month, per medication.

And, if we can’t find a way for you to save money on your brand-name medication, you pay nothing!

Kisunla Patient Assistance Eligibility

General Eligibility Requirements

Kisunla patient assistance qualifications vary depending on the patient assistance program. To know what the medication assistance requirements are, be sure to enroll with Prescription Hope. All patient assistance programs have criteria in several areas, which include:

Income: Different patient assistance programs have different income thresholds for qualification.

Insurance: Different programs also vary in requirements regarding insurance coverage.

Prescription: Qualified patients must hold a prescription for the brand-name medication they wish to obtain.

U.S. Residency: Only legal United States residents can qualify for a patient assistance program.

Simple Enrollment With Expert Support

Getting Started With Enrollment

Looking to enroll in Kisunla assistance? Prescription Hope’s prescription support services can help qualified patients get Kisunla in just 6 steps:

  1. Submit Information: Our online form only takes a few minutes to fill out.
  2. Advocate Contact: After your enrollment form is received, our patient advocates will reach out to you in 1-2 business days.
  3. Document Collection: Our team will collect all your necessary documents after the prequalification period.
  4. Provider Coordination: We will also contact your healthcare provider to obtain any signatures needed.
  5. Program Submission: We will make sure all paperwork is taken care of and submit your paperwork to the patient assistant program on your behalf, continuing to keep in contact with the pharmaceutical manufacturer for you.
  6. Medication Delivery: After approval, patients will normally receive their medication in 2 weeks directly to their door or doctor’s office.

Understanding Kisunla

How Kisunla Works

Kisunla is an amyloid beta-directed monoclonal antibody that targets amyloid beta plaques, abnormal protein deposits that accumulate in the brains of people with Alzheimer’s disease.

After binding to aggregated amyloid beta plaques, Kisunla promotes their removal from the brain. Reducing amyloid plaque buildup may help slow the progression of Alzheimer’s disease during its early symptomatic stages.

Although Kisunla may slow disease progression, it does not cure Alzheimer’s disease or restore memory, thinking abilities, or cognitive function that has already been lost.

What Conditions Does Kisunla Treat?

Kisunla is FDA-approved for the treatment of Alzheimer’s disease.

Treatment should be initiated in adults with early symptomatic Alzheimer’s disease, including:

Before treatment begins, patients should have confirmed evidence of amyloid beta pathology in the brain. Kisunla has been studied in patients during the early stages of Alzheimer’s disease, and this is the population for whom its safety and effectiveness have been established.

Benefits of Treatment

For eligible adults with early Alzheimer’s disease, Kisunla offers a disease-modifying treatment designed to address one of the underlying biological features of the disease rather than simply treating symptoms.

Potential benefits include slowing clinical decline in memory and thinking abilities, slowing worsening of daily functioning, reducing amyloid plaque levels in the brain, slowing progression during the early symptomatic stages of Alzheimer’s disease, and providing a disease-modifying treatment option for appropriately selected patients.

Individual treatment responses vary, and the greatest benefit has been demonstrated when therapy is initiated during the early stages of Alzheimer’s disease.

Important Safety Information and Side Effects

Kisunla carries an FDA Boxed Warning for Amyloid-Related Imaging Abnormalities (ARIA).

ARIA can involve brain swelling (ARIA-E) or small areas of bleeding in the brain (ARIA-H). Although many cases are mild or detected only on routine MRI scans, serious, life-threatening, and fatal intracerebral hemorrhages have occurred.

Patients who carry one or two copies of the APOE ε4 gene have a higher risk of developing ARIA than non-carriers. Healthcare providers should discuss APOE ε4 genetic testing with patients before treatment to help inform the risk of ARIA.

The most commonly reported side effects include amyloid-related imaging abnormalities (ARIA), headache, infusion-related reactions, nausea, and dizziness. Many cases of ARIA are identified only through scheduled brain MRI scans and may not cause noticeable symptoms. Patients should notify their healthcare provider if side effects become severe or persistent.

Patients should discuss the risks of brain swelling or bleeding, serious infusion-related reactions, headache, confusion, dizziness, vision changes, nausea, difficulty walking, focal neurologic deficits, or seizures with their healthcare provider, as these symptoms may indicate ARIA.

Because Kisunla may increase the risk of intracerebral hemorrhage, healthcare providers should carefully evaluate patients receiving anticoagulants, antiplatelet medications, or other therapies that may increase bleeding risk.

A baseline brain MRI is required before treatment begins.

There are no adequate human data regarding Kisunla use during pregnancy. Patients who are pregnant or planning to become pregnant should discuss the potential risks and benefits of treatment with their healthcare provider.

It is unknown whether donanemab-azbt passes into human breast milk. Patients should discuss breastfeeding plans with their healthcare provider before receiving Kisunla.

No clinically significant pharmacokinetic drug interactions are described in the FDA-approved prescribing information. However, healthcare providers should carefully evaluate the use of anticoagulants, antiplatelet medications, and other medications that may increase bleeding risk because of the potential for intracerebral hemorrhage in patients who develop ARIA. Patients should provide a complete list of prescription medications, over-the-counter medicines, vitamins, and herbal supplements before beginning treatment.

Kisunla is administered as an intravenous (IV) infusion by a healthcare professional. The initial dosage is 700 mg every four weeks for the first three doses, followed by 1,400 mg every four weeks thereafter. Infusions are administered over approximately 30 minutes, and patients should be monitored during and after each infusion for infusion-related reactions.

Some patients may discontinue treatment after achieving substantial amyloid plaque removal, based on clinical assessment and the FDA-approved prescribing information.

Healthcare providers routinely monitor baseline and scheduled brain MRI scans, neurologic status, and patients for infusion-related reactions throughout treatment.

Access to Multiple Medications

Support Beyond Kisunla

Patients who are looking for Alzheimer’s medication assistance are often looking for multiple medication assistance programs, since oftentimes they need multiple medications to help maintain their lifestyle.

We offer prescription access help for hundreds of name-brand medications. Every medication on our list that a patient needs and qualifies for, they can get through Prescription Hope’s services for the same price of $70.00 per month, per medication.

Why Choose Prescription Hope for Kisunla Assistance

Patient-Focused Medication Support

For 20 years, Prescription Hope has offered prescription affordability support and patient-centered prescription help to qualified patients across the nation. We are proud to offer Kisunla assistance through Prescription Hope.

Simplified Access to Specialty Medications

Prescription Hope offers all its prescription assistance help at the low cost of $70.00 per month, per medication. That means no fees, add-ons, hidden costs, or even medication costs. Just peace of mind.

Ongoing Prescription Assistance

We are there for you through the application process, advocating on your behalf, but that’s not all we do. We make sure you are supported through the administrative tasks even after you are approved into a patient assistance program. Our team assists with refill scheduling, document updates, yearly renewals, and more.

Network Access

We are proud to be part of a network that has access to hundreds of brand-name medications and their associated patient assistance programs.

If you need Kisunla and don’t know how you’re going to cover the cost, apply to Prescription Hope to see how we can help you save today!

 

Frequently Asked Questions

It's Easy!

Submit Enrollment Form

Getting started is free and easy! Simply complete the online enrollment form. 

Receive Welcome Call

An Enrollment Specialist will reach out to you for a personalized welcome call.

We Manage The Process

Your dedicated team manages your account month after month, allowing you to focus on what matters most—your health.

Helpful Articles

Latest News & Stories

Save Money On Your Prescriptions Today!